Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
Status:
Recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of pyrotinib combined with
trastuzumab and albumin paclitaxel in first-line treatment of HER2-positive advanced or
metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University